The Hsp90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin increases cisplatin antitumor activity by inducing p53-mediated apoptosis in head and neck cancer.
about
Targeting Hsp90 in urothelial carcinomaMutant glucocerebrosidase in Gaucher disease recruits Hsp27 to the Hsp90 chaperone complex for proteasomal degradationp63 threonine phosphorylation signals the interaction with the WW domain of the E3 ligase ItchHSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation.Glucocorticoid Receptor-Targeted Liposomal Codelivery of Lipophilic Drug and Anti-Hsp90 Gene: Strategy to Induce Drug-Sensitivity, EMT-Reversal, and Reduced Malignancy in Aggressive Tumors.Heat shock protein 90 inhibitors augment endogenous wild-type p53 expression but down-regulate the adenovirally-induced expression by inhibiting a proteasome activity.
P2860
The Hsp90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin increases cisplatin antitumor activity by inducing p53-mediated apoptosis in head and neck cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The Hsp90 inhibitor 17-
@nl
The Hsp90 inhibitor 17-(allyla ...... tosis in head and neck cancer.
@en
type
label
The Hsp90 inhibitor 17-
@nl
The Hsp90 inhibitor 17-(allyla ...... tosis in head and neck cancer.
@en
prefLabel
The Hsp90 inhibitor 17-
@nl
The Hsp90 inhibitor 17-(allyla ...... tosis in head and neck cancer.
@en
P2093
P2860
P356
P1476
The Hsp90 inhibitor 17-(allyla ...... tosis in head and neck cancer.
@en
P2093
P2860
P2888
P356
10.1038/CDDIS.2013.488
P577
2013-12-12T00:00:00Z
P5875
P6179
1043859498